Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Tetanus × sargramostim × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 33 Leukemia 31 Melanoma 26 Lymphoma, Non-Hodgkin 20 Lymphoma, Follicular 20 Leukemia, Lymphocytic, Chronic, B-Cell 20 Breast Neoplasms 19 Precursor Cell Lymphoblastic Leukemia-Lymphoma 17 Lymphoma, Large B-Cell, Diffuse 17 Lymphoma, Mantle-Cell 16 Neuroblastoma 15 Lymphoma, Large-Cell, Immunoblastic 14 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13 Prostatic Neoplasms 12 Myelodysplastic Syndromes 12 Carcinoma, Non-Small-Cell Lung 12 Burkitt Lymphoma 12 Neoplasm Metastasis 11 Multiple Myeloma 11 Lung Neoplasms 11 Hodgkin Disease 11 Lymphoma, B-Cell, Marginal Zone 10 Leukemia, Myeloid, Chronic-Phase 10 Glioblastoma 10 Leukemia, Myeloid, Acute 9 Carcinoma, Ovarian Epithelial 9 Ovarian Neoplasms 8 Gliosarcoma 8 Fallopian Tube Neoplasms 7 Central Nervous System Neoplasms 7

Interventions

sargramostim 1 Temozolomide 1 Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03927222 2024-04-08

I-ATTAC

Duke University

Phase 2 Terminated

6 enrolled 7 charts

Glioblastoma, Tetanus

Data powered by HemOnc (CC BY 4.0) Colophon ⚡